Menu

Image of the Day: Fungal Fireworks

The fungus Aspergillus fumigatus begins to grow biofilms as it develops into a larger intertwined network.

Jun 26, 2017
The Scientist Staff

A time-lapse laser-scanning confocal microscopy video depicts Aspergillus fumigatus growth on media, imaged every 20 minutes for 20 hours.

BRENDAN SNARR, RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE

 A. fumigatus rapidly develops biofilms, which protect the microbe from drugs and its host's immune defenses, according to a news release. Scientists were able to disrupt A. fumigatus’s biofilm-forming abilities with polysaccharide-degrading enzymes derived from the microbes themselves.

"We were able to use the microbe's own tools against them to attack and destroy the sugar molecules that hold the biofilm together," says Don Sheppard, director of the Division of Infectious Diseases at the McGill University Health Centre and a lead author on the study, in the release.

See B.D. Snarr et al., “Microbial glycoside hydrolases as antibiofilm agents with cross-kingdom activity,” BioRxiv, doi:10.1073/pnas.1702798114, 2017.

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

Every minute counts when waiting for accurate diagnostic test results to guide critical care decisions, making today's clinical lab more important than ever. In fact, nearly 70 percent of critical care decisions are driven by a diagnostic test.

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN Ltd are pleased to announce the commercial licensing of CRISPR-Cas9 gene-editing technology from Broad Institute of MIT and Harvard in the USA, to develop human cell disease models to support preclinical metabolic disease therapeutic programmes.